Trial reportTrials2011
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Trial report in Trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Topical microbicides for preventing sexually transmitted infections.The Cochrane database of systematic reviews · 2021Pooled it
- Pre-exposure prophylaxis for the prevention of HIV infection in high risk populations: a meta-analysis of randomized controlled trials.PloS one · 2014Pooled it
- Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa.BMC public health · 2017Trial
- Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection.The New England journal of medicine · 2015Trial
- Limited HIV-1 superinfection in seroconverters from the CAPRISA 004 Microbicide Trial.Journal of clinical microbiology · 2014Trial
- Issues in women's participation in a phase III community HIV vaccine trial in Thailand.AIDS research and human retroviruses · 2013Trial
- Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial.Obstetrics and gynecology · 2011Trial
- HPV infection and the genital cytokine milieu in women at high risk of HIV acquisition.Nature communications · 2019Article
- Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women.Nature medicine · 2018Article
- Integrin αScience translational medicine · 2018Article
- Article
- At the Heart of the Problem: Health in Johannesburg's Inner-City.BMC public health · 2017Article
- Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.Molecules (Basel, Switzerland) · 2015Article
- Combination HIV prevention for female sex workers: what is the evidence?Lancet (London, England) · 2015Article
- Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa.Nature communications · 2014Article
- Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches.Current HIV/AIDS reports · 2014Review
- An assessment of the likely acceptability of vaginal microbicides for HIV prevention among women in rural Ghana.BMC women's health · 2012Article
- Innate immune activation enhances hiv acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.The Journal of infectious diseases · 2012Article
- Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.Journal of translational medicine · 2012Article
- A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.Expert opinion on investigational drugs · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundYoung women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for sexually active women who are unable to successfully negotiate mutual monogamy or condom use. PURPOSE: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa.
methodsThis analysis assessed the baseline demographic, clinical and sexual behavior data of women screened and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as means and percent for categorical variables.
resultsHIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in exchange for sex (p < 0.001).
conclusionThe populations selected provide suitable diverse target groups for HIV prevention intervention studies.
trial registrationClinicalTrials.gov: NCT 00441298.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.